^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) + Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Tolerability of ALK/MET Combinations in Patients with ALK-Rearranged Lung Cancer with Acquired MET Amplification: A Retrospective Analysis
Published date:
05/31/2023
Excerpt:
We assembled a cohort of patients with ALK+ lung cancer and acquired MET amplification (identified by tissue or plasma) who received regimens targeting both ALK and MET....Partial responses were observed in 5 (42%) of 12 patients, including patients who received crizotinib (n=1 of 2), lorlatinib + crizotinib (n=3 of 6), and alectinib + capmatinib (n=1 of 3).
DOI:
https://doi.org/10.1016/j.jtocrr.2023.100534
